Notably, an anti-CD133-drug conjugate exhibited significant suppression of hepatocellular and gastric cancers [175], while polymeric nanoparticles targeting CD133 exhibited tumor-killing effects in breast cancer [176]. This evidence concerns the gene PROM1 and neoplasm.